Gallacher Capital Management LLC Acquires Shares of 7,568 Alkermes plc (NASDAQ:ALKS)

Gallacher Capital Management LLC bought a new position in shares of Alkermes plc (NASDAQ:ALKSFree Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 7,568 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC bought a new stake in shares of Alkermes during the fourth quarter worth $25,000. EverSource Wealth Advisors LLC lifted its position in Alkermes by 106.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock valued at $47,000 after purchasing an additional 842 shares during the period. Blue Trust Inc. boosted its stake in shares of Alkermes by 2,231.5% in the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock valued at $49,000 after purchasing an additional 1,629 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Alkermes by 558.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock worth $85,000 after buying an additional 2,502 shares during the period. Finally, KBC Group NV raised its stake in shares of Alkermes by 18.8% during the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after buying an additional 774 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Stock Performance

Shares of Alkermes stock opened at $34.03 on Monday. The firm has a market cap of $5.53 billion, a PE ratio of 15.68, a P/E/G ratio of 2.20 and a beta of 0.62. The business’s 50 day simple moving average is $32.38 and its 200 day simple moving average is $29.86. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45.

Alkermes (NASDAQ:ALKSGet Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. As a group, equities research analysts predict that Alkermes plc will post 1.31 EPS for the current year.

Wall Street Analysts Forecast Growth

ALKS has been the topic of a number of recent research reports. The Goldman Sachs Group raised their price objective on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 14th. HC Wainwright reaffirmed a “neutral” rating and set a $46.00 price objective on shares of Alkermes in a research note on Thursday, February 13th. UBS Group raised Alkermes from a “sell” rating to a “neutral” rating and increased their target price for the company from $21.00 to $38.00 in a research note on Tuesday, March 4th. StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada started coverage on shares of Alkermes in a research report on Thursday. They issued a “sector perform” rating and a $40.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.46.

View Our Latest Research Report on Alkermes

Insider Transactions at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the sale, the executive vice president now directly owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. This represents a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 4.89% of the company’s stock.

Alkermes Profile

(Free Report)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Further Reading

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKSFree Report).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.